UroNav MRI/Ultrasound Fusion-Guidance For Accurate Sampling and Results
Performing a biopsy with MRI-Ultrasound fusion holds the potential to target the suspicious area, reduce the number of tissue samples acquired, and thus may reduce the risk of infection, bleeding, pain, and recovery time.
Are You A Candidate For UroNav?
What makes a good candidate for UroNav?
- Patients with elevated Prostate-specific Antigen (PSA) level > 4
- Negative prior trans-rectal Ultrasound-guided biopsy with continued elevation or rising PSA
- Positive digital rectal examination with negative trans-rectal Ultrasound biopsy
Current Diagnosis Standards
What are the current standards?
- PSA (Prostate Specific Antigen) blood test
- DRE (Digital Rectal Exam)
- If DRE finding or PSA level is abnormal a TRUS (transrectal ultrasound-guided) biopsy is recommended
- Follow-up for Negative Biopsies is repeating the PSA test periodically
Benefits of MRI/US Fusion Biopsy
Benefits of UroNav:
- Provides a 3-D view of the prostate
- GPS-like system guides the biopsy needle
- Reduces discomfort
- Reduces the risk of overlooking a tumor
- Improves accuracy & diagnosis
Prostate Cancer Facts You Cannot Ignore
Approximately 1 in 6 men are diagnosed with prostate cancer in their lifetime. Compare to 1 in 8 women developing breast cancer.
Second to skin cancer, prostate cancer is the most common cancer in American men, causing over 26,000 deaths in 2017.
Prostate cancer is the third leading cause of cancer death in American men. About 1 in 39 men die of prostate cancer.
The incidence of prostate cancer has increased by 1.7% in the US between 1995 & 2002.
Introducing Dr. Robert Wake, Chairman of the Department of Urology at the University of Tennessee
Dr. Robert Wake is Chairman of the Department of Urology at the University of Tennessee Health Science Center. He completed his Medical School at the University of Tennessee in 1985 where he received the honor of being elected to the Alpha Omega Alpha (AOA) medical society. He then completed his Urology residency at the University of Tennessee in 1990. After this residency, he joined the faculty at UT and has served as Program Director and Vice-Chairman prior to his current position.
Dr. Wake has a special interest in the treatment and research of prostate cancer and its complications, as well as kidney stone disease. Dr. Wake was also one of the first to perform and report on a large series of 2nd generation Targeted Cryoablation of the Prostate.
“With the framework set up at the East Campus, we are well on the way to creating comprehensive men’s health services. We want to provide a friendly and comfortable environment where men can come in for most of their health concerns, from blood pressure and cholesterol to erectile dysfunction or prostate issues, and be cared for by providers who will address those concerns with them.” – Dr. Wake
The UroNav Fusion Biopsy Procedure Now Available At Regional One Health
Early and accurate detection of prostate cancer is a vital component to a positive prognosis. Regional One Health is now using a new technology to diagnosis prostate tumors that were previously missed using the standard prostate biopsy technique. Previously the prostate biopsy procedure was just a random sampling of the peripheral zones of the prostate hoping to identify prostate cancer that could not be seen by ultrasound.
This new procedure is available at Regional One Health and is being performed by Robert Wake, MD, a urologist with UT Regional One Physicians and Chairman of the Department of Urology at the University of Tennessee Health Science Center. Dr. Wake is a respected leader in the field of urology and has a special interest in the treatment and research of prostate cancer and its complications.